Floatz logo

Osimertinib

EGFR Exon 19 Deletion

Peking Union Medical College HospitalSmall moleculePhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the EGFR Exon 19 Deletion cohort.

Asset / SponsorPhaseRating
Patritumab Deruxtecan
Daiichi Sankyo
Phase 3B

Same molecule, other indications

Osimertinib is also rated in:

EGFR Activating MutationDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
lung adenocarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →